{"entity":{"id":"vispacabtagene-regedleucel","kind":"drug","name":"Vispacabtagene regedleucel","aka":["CB-010","vispa-cel"],"tldr":"Vispacabtagene regedleucel is an experimental allogeneic CAR-T cell therapy from Caribou Biosciences, in phase 1 trials for relapsed or refractory B cell non-Hodgkin lymphoma.","summary":"Vispacabtagene regedleucel (CB-010, vispa-cel) is an allogeneic CAR-T cell therapy (CRISPR chRDNA genome-edited) from Caribou Biosciences. An allogeneic anti-CD19 CAR-T cell therapy made with Cas9 chRDNA guides: the TRAC gene is knocked out to remove the T cell receptor, the anti-CD19 CAR is inserted into TRAC, and PD-1 is knocked out, a strategy designed to limit premature CAR-T cell exhaustion. Its furthest stage is phase 1, for relapsed or refractory B cell non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Company calls it its lead clinical-stage program; registry NCT04637763 (phase 1) is active, not recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Caribou Biosciences: cariboubio.com","url":"https://www.cariboubio.com/pipeline"},{"label":"Caribou Biosciences: cariboubio.com","url":"https://www.cariboubio.com/pipeline"},{"label":"Caribou Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT04637763"},{"label":"ClinicalTrials.gov: trials of CB-010","url":"https://clinicaltrials.gov/search?intr=CB-010"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["caribou"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04637763"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CB-010","modality":"Allogeneic CAR-T cell therapy (CRISPR chRDNA genome-edited)","mechanism":"An allogeneic anti-CD19 CAR-T cell therapy made with Cas9 chRDNA guides: the TRAC gene is knocked out to remove the T cell receptor, the anti-CD19 CAR is inserted into TRAC, and PD-1 is knocked out, a strategy designed to limit premature CAR-T cell exhaustion.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vispacabtagene-regedleucel/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/"}],"trial":[{"id":"nct04637763","kind":"trial","name":"CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)","route":"/trials/nct04637763/"}]}}